SOURCE: Wall Street News Alert

April 12, 2006 09:44 ET

Stock Watch: POSC Is on the Move! April 12, 2006

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL -- (MARKET WIRE) -- April 12, 2006 -- Wall Street News Alert's "stocks to watch" this morning are: Positron Corporation (OTC BB: POSC), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Johnson & Johnson (NYSE: JNJ) and Bausch & Lomb (NYSE: BOL).

Based on the company's new product announcement, Positron Corporation (OTC BB: POSC) may be on the screen of aggressive investors and day traders this morning! Yesterday after the stock markets closed, the company issued a press release announcing that it has finalized an agreement with the University of Texas at Houston and the Weatherhead PET Center headed by Dr. K. Lance Gould granting Positron a license to develop and commercialize an integrated comprehensive software system developed for the major diagnostic and management needs in coronary artery disease.

News of the license to develop and commercialize should get the attention of investors! The software system includes the validated quantification of coronary blood flow images by PET Longitudinal Gradient Analysis and Homogeneity Algorithm (LGA/HA) to determine severity of coronary disease as the objective non-invasive basis for or against coronary bypass surgery or stent procedures and the automated objective analysis of CT or invasive coronary angiograms and a comprehensive database management system. The addition of the LGA/HA enables the Positron device to identify early coronary artery disease before clinically significant blockages develop. The quantitative accuracy provides non-invasive follow-up of treatment effectiveness in long-term studies documenting the prevention, stabilization or reversal of coronary artery disease in most patients. The Coronary Arteriographic Tree analysis program integrates 35 years of fluid dynamic research into automated quantification of the entire coronary artery tree for diffuse atherosclerosis as well as multiple blockages in all coronary arteries and branches on a CT or invasive coronary arteriogram. It therefore avoids the common visual overestimation of severity that leads to unnecessary bypass surgery or angiogram catheter procedures. The basis for these three applications has been proven in high quality scientific journals including Circulation, the Journal of the American College of Cardiology, the Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.

Continue to watch this company! This integrated clinical software bundle is an essential part of Positron's product solutions that further differentiates Positron from larger PET manufactures through its superior integrated cardiac PET products in the growing cardiac PET market.

Investors should continue to research the progress of Positron! In conjunction with Positron's software R&D efforts, the Company also announced the release of Positron version A3.7 software. Griff Miller, EVP of Software and IT of Positron stated, "The release of A3.7 is the culmination of more than a decade of data and up-to-date development based on the demands of the PET imaging industry and feedback from our customers and Positron's application specialists."

Wall Street News Alert is continuing to place Aggressive Investors on alert to monitor the progress of Positron! Joseph Oliverio, President of Positron, stated, "The addition of these software systems signifies a critical piece to our further development of state of the art technology and the execution of our business plan. Our comprehensive integrated hardware-software package for total cardiac solutions are ideal for hospitals wanting to differentiate their diagnostic and therapeutic services from competing traditional heart surgery centers. With this software we can bridge the prior critical deficiencies with our integrated quantification of coronary anatomy by CTA, myocardial perfusion and heart function by PET imaging. The release of A3.7 and with the enhancements for quantification will allow Positron users to compete for cholesterol lowering drug trails that assess coronary artery disease reversal thanks to the success Dr. K. Lance Gould has demonstrated using the software as proven in high quality scientific journals."

Prior to the latest press release, the stock closed yesterday at Thirteen cents a share.

For an in-depth profile of Positron Corporation, visit http://www.thenewssvc.com/POSC041106.html

To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.

In case you are not familiar with the company: Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM™ systems. POSICAM™ systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM™ systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) down 2.2% on 11.4 million shares traded. Teva Pharmaceutical Industries Ltd. is among the top pharmaceutical companies.

Johnson & Johnson (NYSE: JNJ) up 0.07% on 9.1 million shares traded.

Johnson & Johnson is a manufacturer of health care products.

Bausch & Lomb (NYSE: BOL) down 14.6% on 26.7 million shares traded.

Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world.

Commentary:

"The cable companies are looking for ways to expand their usage and shrink your wallet. Cable executives are trying to get viewers to use key-services like on-demand viewing more often. Both CBS and NBC signed deals this year with Comcast to offer replays of hit shows for 99 cents. ABC has yet to sign a deal, but with hit shows like 'Lost,' 'Desperate Housewives' and 'Grey's Anatomy' on-demand is looking good," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com.

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at info@wallstreetnewsalert.com

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 50 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button.

*** Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street! If you receive any such fax, please do not contact us at www.wallstreetnewsalert.com. You may wish to inquire about the fax, with the CEO of the company that the fax is written about ***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated Twenty-Five Thousand Dollars for coverage of Positron Systems Inc., (OTC BB: POSC), by a third party (CLX & Associates Inc.), who is non-affiliated and may hold a significant position in the stock, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information